Bulletin
Investor Alert

press release

Oct. 27, 2021, 7:15 a.m. EDT

ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021

LAUSANNE, Switzerland, (BUSINESS WIRE) -- ADC Therapeutics SA /zigman2/quotes/214411413/composite ADCT -6.80% , a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a conference call and live webcast on Tuesday, November 2, 2021, at 8:30 a.m. EDT to report financial results for the third quarter 2021 and provide business updates.

To access the live call, please dial 833-303-1198 (domestic) or +1 914-987-7415 (international) and provide conference ID 4035885. A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com . The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics /zigman2/quotes/214411413/composite ADCT -6.80% is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA [®] (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn .

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005253/en/

SOURCE: ADC Therapeutics SA

Investors
Eugenia Litz
ADC Therapeutics
Eugenia.Litz@adctherapeutics.com
Tel.: +44 7879 627205 Amanda Hamilton
ADC Therapeutics
amanda.hamilton@adctherapeutics.com
Tel.: +1 917 288 7023 EU Media
Alexandre Müller
Dynamics Group
amu@dynamicsgroup.ch
Tel: +41 (0) 43 268 3231 USA Media
Mary Ann Ondish
ADC Therapeutics
maryann.ondish@adctherapeutics.com
Tel.: +1 914-552-4625

COMTEX_395886337/2456/2021-10-27T07:15:24

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2021

/zigman2/quotes/214411413/composite
US : U.S.: NYSE
$ 14.67
-1.07 -6.80%
Volume: 143,037
Jan. 27, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.21 billion
Rev. per Employee
$81,284
loading...
/zigman2/quotes/214411413/composite
US : U.S.: NYSE
$ 14.67
-1.07 -6.80%
Volume: 143,037
Jan. 27, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.21 billion
Rev. per Employee
$81,284
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.